EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) is projected to announce its earnings results before the market opens on Wednesday, March 5th. Analysts expect the company to announce earnings of ($0.54) per share and revenue of $11.02 million for the quarter. Individual interested in listening to the company's earnings conference call can do so using this link.
EyePoint Pharmaceuticals Stock Up 0.6 %
Shares of EYPT traded up $0.04 during mid-day trading on Friday, reaching $6.27. The company had a trading volume of 640,091 shares, compared to its average volume of 848,287. The stock has a market capitalization of $427.93 million, a P/E ratio of -3.14 and a beta of 1.51. The stock has a 50 day moving average of $7.34 and a two-hundred day moving average of $8.51. EyePoint Pharmaceuticals has a 52-week low of $5.78 and a 52-week high of $28.79.
Analyst Ratings Changes
A number of equities research analysts have recently commented on the company. Citigroup initiated coverage on EyePoint Pharmaceuticals in a research report on Tuesday, January 7th. They set a "buy" rating and a $33.00 target price on the stock. HC Wainwright reiterated a "buy" rating and set a $22.00 target price on shares of EyePoint Pharmaceuticals in a research report on Thursday, December 5th. Chardan Capital reissued a "buy" rating and issued a $33.00 price target on shares of EyePoint Pharmaceuticals in a report on Thursday, February 6th. Finally, Robert W. Baird decreased their price objective on shares of EyePoint Pharmaceuticals from $38.00 to $33.00 and set an "outperform" rating on the stock in a report on Monday, November 11th. One research analyst has rated the stock with a sell rating and nine have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $26.63.
View Our Latest Research Report on EyePoint Pharmaceuticals
EyePoint Pharmaceuticals Company Profile
(
Get Free Report)
EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.
Further Reading
Before you consider EyePoint Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and EyePoint Pharmaceuticals wasn't on the list.
While EyePoint Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
